Optimal ESR1 Testing Strategies in HR+/HER2- Metastatic Breast Cancer

News
Video

In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.

Related Videos
Experts on breast cancer
Expert on GVHD
Expert on breast cancer
Experts on breast cancer
Expert on GVHD
Experts on GVHD
Expert on breast cancer
Experts on breast cancer
Expert on GVHD
Related Content